Milestone Alert: Last Patient Completes 1-year Follow-up in Phase 3 Study of Ameluz-PDT in sBCC
The last patient in Biofrontera’s Phase 3 study of Ameluz and RhodoLED PDT in superficial basal cell carcinoma (sBCC) completed their one-year follow-up visit in December of 2024. The double-blind, randomized, placebo-controlled, multi-center ALA-BCC-CT013 study evaluated safety and efficacy in 187 patients with one or more clinically and histologically confirmed superficial BCCs. They each received […]